TC
REGN icon

TFS Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

TFS Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-920
Closed -$452K – 286
2017
Q2 		$452K Sell
920
-319
-26% -$140K 0.18% 199
2017
Q1 		$480K Buy
+1,239
New +$459K 0.16% 203

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TFS Capital's REGN Position: Q3 2017 in Review

TFS Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2017, closing a stake of 920 shares — an estimated $452K sold.

TFS Capital first reported a position in REGN in Q1 2017 and held it in 2 quarters. The position peaked at $480K in Q1 2017. 605 funds tracked by Wall St. Rank hold REGN as of Q3 2017.

  • TFS Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 920 Regeneron Pharmaceuticals shares in Q3 2017, an estimated $452K.
  • TFS Capital first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • TFS Capital's Regeneron Pharmaceuticals position peaked at $480K in Q1 2017.
  • 605 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.